Corbus Pharmaceuticals (3371) Price & Analysis

0 Followers

3371 Stock Chart & Stats

€8.32

-€0.10(-0.85%)

At close: Jan 08 4:00 PM EST

€8.32

-€0.10(-0.85%)

Day’s Range― - ―

52-Week Range€5.70 - €18.40

Previous CloseN/A

Volume0.00

Average Volume (3M)98.00

Market Cap

€149.84M

Enterprise Value€76.07M

Total Cash (Recent Filing)€138.60M

Total Debt (Recent Filing)€1.21M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Aug 11, 2026

EPS Estimate

-1.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.31

Shares Outstanding18,527,796

10 Day Avg. Volume164

30 Day Avg. Volume98

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.73

Price to Sales (P/S)0.00

P/FCF Ratio-1.68

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€32.80

Price Target Upside294.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-4.08

Revenue Forecast (FY)€1.46M

Bulls Say, Bears Say

Bulls Say

CRB-701 Clinical EfficacyRobust Phase 1/2 objective responses with durable activity and manageable safety create a durable clinical signal. If replicated in registrational trials, these efficacy and biomarker-linked results can establish CRB-701 as a differentiated ADC in HPV-driven tumors, improving commercial and partnership prospects over the medium term.

Regulatory Alignment For Registrational PathClear FDA alignment reduces regulatory uncertainty and defines acceptable endpoints and trial design. That clarity enables efficient protocol development, resource allocation and faster move to randomized registrational studies, materially improving the probability and timeline for a potential accelerated approval pathway.

Cash Runway And Low LeverageA multi-year cash runway coupled with very low reported leverage gives the company financial flexibility to advance CRB-701 registrational studies and the CANYON-1 obesity program without immediate dilutive raises. This reduces near-term funding risk and supports continued clinical investment over the next 2–3 years.

Bears Say

No Product Revenue; Widening LossesAs a pre-revenue biotech, Corbus depends entirely on financing and partnerships while incurring rising operating losses. Continued negative profitability without product sales increases reliance on capital markets, risks equity erosion, and constrains long-term investment if clinical timelines slip or approvals are delayed.

Accelerating Operating Cash BurnSteadily increasing cash burn consumes balance sheet resources and can force dilutive financing or scaling back programs if unaddressed. Even with stated runway, sustained negative FCF raises structural funding risk for late-stage trials and commercialization preparations, pressuring strategic choices over the medium term.

Key Clinical Leadership DepartureLoss of the chief medical officer during transition to registrational-stage development can disrupt trial execution, regulatory interactions and protocol finalization. Replacing clinical leadership amid pivotal program launches may delay timelines or complicate consistency in data generation and regulatory strategy.

Corbus Pharmaceuticals News

Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho

Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $34 from $44 and...

10d ago

CRBP

Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer

Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $52 from $54 and keeps an Outperform...

16d ago

CRBP

Corbus Pharmaceuticals management to meet with Oppenheimer

Dinner Meeting with management to be held on June 15 hosted by Oppenheimer. Published first on TheFly –...

23d ago

CRBP

Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush

Wedbush lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $30 from $38 as the firm refines...

1M ago

CRBP

Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Corbus Pharmaceuticals, with...

1M ago

CRBP

Corbus Pharmaceuticals share selloff overdone, says Guggenheim

Guggenheim views the weakness today in shares of Corbus Pharmaceuticals (CRBP) as overdone. The company’s CRB-701 data supports...

1M ago

CRBP

Buy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Corbus Pharmaceuticals,...

1M ago

CRBP

Corbus Highlights Promising CRB-701 Data in HPV Cancers

An update from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On May 26, 2026, Corbus reported updated...

1M ago

CRBP

Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data

Corbus Pharmaceuticals (CRBP) reported updated data from its Phase 1/2 clinical study of CRB-701. The new data demonstrate...

1M ago

CRBP

Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $44 from $40 and...

1M ago

CRBP

Corbus Pharmaceuticals Appoints First Chief Business Officer

The latest announcement is out from Corbus Pharmaceuticals ( ($CRBP) ). On May 21, 2026, Corbus Pharmaceuticals appointed...

1M ago

CRBP

Corbus Pharmaceuticals names Nishant Saxena as chief business officer

Corbus announced the appointment of former Evercore managing director Nishant Saxena as the company’s first chief business officer,...

1M ago

CRBP

Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates

An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On May 13, 2026, Corbus Pharmaceuticals’ board...

2M ago

CRBP

Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential

Oliver McCammon, an analyst from LifeSci Capital, maintained the Buy rating on Corbus Pharmaceuticals. The associated price target...

2M ago

CRBP

3371 FAQ

What was Corbus Pharmaceuticals’s price range in the past 12 months?

Corbus Pharmaceuticals lowest stock price was €5.70 and its highest was €18.40 in the past 12 months.

What is Corbus Pharmaceuticals’s market cap?

Corbus Pharmaceuticals’s market cap is €149.84M.

When is Corbus Pharmaceuticals’s upcoming earnings report date?

Corbus Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 39 days.

How were Corbus Pharmaceuticals’s earnings last quarter?

Corbus Pharmaceuticals released its earnings results on May 12, 2026. The company reported -€1.075 earnings per share for the quarter, missing the consensus estimate of -€1.068 by -€0.008.

Is Corbus Pharmaceuticals overvalued?

According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corbus Pharmaceuticals pay dividends?

Corbus Pharmaceuticals does not currently pay dividends.

What is Corbus Pharmaceuticals’s EPS estimate?

Corbus Pharmaceuticals’s EPS estimate is -1.1.

How many shares outstanding does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals has 18,527,796 shares outstanding.

What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?

Corbus Pharmaceuticals reported an EPS of -€1.075 in its last earnings report, missing expectations of -€1.068. Following the earnings report the stock price went up 0.889%.

Which hedge fund is a major shareholder of Corbus Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:3371

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Corbus Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-70.89%

Trailing 12-Months

Asset Growth

3.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals (3371) Earnings & Revenues

Historic Earnings Reports

3371 Stock 12 Month Forecast

Average Price Target

€32.80

▲(294.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","25":"€25","46":"€46","14.5":"€14.5","35.5":"€35.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45.67938856,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€45.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.795458453333325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€32.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.596593839999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€24.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,14.5,25,35.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.895,10.801491427692307,13.707982855384614,16.614474283076923,19.52096571076923,22.427457138461534,25.333948566153843,28.24043999384615,31.146931421538458,34.05342284923077,36.95991427692307,39.866405704615374,42.77289713230769,{"y":45.67938856,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.895,9.81041988102564,11.72583976205128,13.641259643076921,15.556679524102561,17.4720994051282,19.387519286153843,21.30293916717948,23.218359048205123,25.133778929230765,27.049198810256403,28.964618691282045,30.880038572307686,{"y":32.795458453333325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.895,9.179737987692308,10.464475975384614,11.749213963076922,13.033951950769229,14.318689938461537,15.603427926153845,16.88816591384615,18.17290390153846,19.457641889230768,20.742379876923074,22.027117864615384,23.31185585230769,{"y":24.596593839999997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.065,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.855,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.895,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >